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EFFECTS OF PHARMACOLOGICAL INACTIVATION OF ADENOSINE 
2A RECEPTORS IN A MURINE MODEL OF POLYMICROBIAL SEPSIS 
 
BRIAN J. HELBIG 
 
ABSTRACT 
 
 Sepsis is a worldwide health problem with an enormous economic 
burden and devastatingly high mortality rate. The pathophysiology and 
immune dysfunctions that occur during sepsis remain largely unknown, 
severely limiting current treatment options for sepsis.  Both the innate 
and adaptive parts of the immune system are known to be involved in the 
dysfunctions that occur during sepsis. Over the last few years adenosine 
has been recognized as an endogenous mediator that alters both innate 
and adaptive immune responses. Adenosine receptors are largely 
expressed on many different immune cells and may serve to limit excess 
collateral damage in the setting of inflammation. In this study, the 
pharmacological effects of an A2A receptor antagonist on septic mice were 
examined using the CLP model of sepsis that results in a polymicrobial 
infection. Pharmacological inactivation of the A2A receptor significantly 
increased mortality in septic mice predicted to live in comparison to 
those given only vehicle. Treatment with the A2A receptor antagonist also 
increased expression of CD40, part of a pathway well known for its roles 
		 vii 
in inflammation. Our data also showed increased monocyte MHCII 
expression after treatment with an adenosine antagonist. Our data 
support the role that A2A receptors are involved in the immune response 
to sepsis, and that these receptors may serve to damage excess collateral 
damage ensuing from the host immune response, and that additional 
studies on adenosine and its related purine nucleosides would be of use 
for better understanding of the immune dysfunctions that occur during 
sepsis and other diseases. 
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INTRODUCTION 
 
Sepsis Epidemiology 
Sepsis is an increasing global health problem. It is the number one 
cause of deaths in intensive care units and claims an estimated 250,000 
deaths in the United States each year (Vincent, 2013). Sepsis is also a 
huge economic burden for the world, costing an estimated 24 billion 
dollars each year, an increase of nearly 60% from 2003 to 2007 (Lagu, 
2012). 
Defining sepsis is a difficult task because of its varied etiologies, 
presentation, stages, and outcomes. Historically, sepsis was defined as a 
systemic response to infection (Bone, 1989). To further clarify the terms 
associated with sepsis, an international sepsis conference met in 1991, 
where it was proposed that the system inflammatory response syndrome 
(SIRS) would be defined when two or more of the following criteria seen in 
table 1 were met. 
Parameter Value 
Body Temperature >38°C(100.4°F) OR <36°C (96.8°F) 
Heart Rate >90 beats per minute 
Tachypnea Respiratory rate >20 breaths per minute OR a 
PaCO2 <32 mm Hg 
Abnormal WBC 
Count 
>12,000 cells/µL OR <4,000 cells/µL, OR >10% 
band cells 
 
Table 1: Systemic Inflammatory Response Syndrome Criteria  
(adapted by Bone, 1992). Two or more of these criteria are required for 
diagnosis of SIRS. 
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When SIRS results from infection it is termed sepsis. Severe sepsis 
is defined as sepsis associated with organ dysfunction, hypoperfusion, or 
hypotension. Septic shock is defined as severe sepsis with hypotension 
that persists despite adequate fluid resuscitation (Bone, 1992).  
The mortality of sepsis ranges from approximately 20% in sepsis to 
over 60% seen in septic shock (Brun-Buisson, 2003). Despite 
improvements in healthcare, the mortality in sepsis remains staggeringly 
high and the incidence is actually increasing over time. Many factors 
may contribute to the increasing incidence, such as a longer life 
expectancy as well as the emergence of treatment-resistant infectious 
agents.  The six most common infection sites that result in sepsis are 
pneumonia, blood-stream infections (including infective endocarditis), 
intravascular catheter-related sepsis, intra-abdominal infections, uro-
sepsis, and surgical wound infections (Calandra, 2005). 
 
Pathophysiology 
Based on the early initial clinical presentation of sepsis (fever, 
shock, and organ dysfunction), it was initially speculated that sepsis was 
the result of a massive inflammatory reaction from the host’s innate 
immune system in response to an infectious agent. This lead to intense 
research on anti-inflammatory treatments for sepsis aimed at controlling 
inflammation and dampening the so-called cytokine storm (Hotchkiss, 
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2003) (Freeman, 2000). Results from animal studies showed promising 
results, but in human phase III clinical trials only some cases improved, 
while many were unaffected or actually suffered increased mortality. This 
finding that only certain subsets of patients improved from anti-
inflammatory treatments while others were harmed indicated that sepsis 
was a more complicated syndrome than initially thought and not simply 
due to an exaggerated inflammatory immune response (Fisher, 1996) 
(Remick, 1992) (Zeni, 1997).  
 
Immunosuppression 
Improved treatment strategies have resulted in most patients 
surviving the initial phase of sepsis. It has been found that these septic 
survivor patients later show signs of significant immunosuppression 
(Hotchkiss, 2003). Significant lymphocyte apoptosis occurs during sepsis 
that leaves the host vulnerable to new infections and unable to clear the 
initial septic insult. Septic patients experience loss of delayed 
hypersensitivity, increased risk for opportunistic infections, reactivation 
of latent viruses such as cytomegalovirus and HSV, decreased 
production of inflammatory mediators, and an inability to clear infection 
(Limaye, 2008). A post-mortem study by Torgerson found that 
approximately 80% of septic patients had uncleared septic foci at the 
time of death (Torgerson, 2009). In another study, the ability of 
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monocytes to secrete TNFα and IL-6 when exposed to endotoxin was 
severely reduced in septic patients (Heagy, 2000). These studies indicate 
that sepsis causes enduring immune dysfunctions that can also affect 
the adaptive immune system, in addition to the innate immune system, 
and cause significant immunosuppression. The idea of a Compensatory 
Anti-inflammatory Response Syndrome (CARS) was introduced to 
describe the host’s immune changes that attempt to limit inflammation 
during pathological conditions and restore homeostasis (Bone, 1996). 
The compensatory anti-inflammatory response syndrome involves 
cellular changes including an increase in lymphocyte apoptosis, 
decreased expression of human leukocyte antigen (HLA) receptors on 
antigen-presenting cells, decreased responsiveness of monocytes when 
stimulated, and increased production of anti-inflammatory cytokines 
such as IL-10 (Volk, 1996). CARS serves to limit damage caused by 
excessive inflammation and represents an inherent negative feedback 
mechanism for the immune system to control excessive inflammation. 
More recent studies have shown that early sepsis is characterized 
by both a rapid release of pro-inflammatory and anti-inflammatory 
cytokines, and that this balance is important for the host response and 
survival (Munford, 2001). It is now commonly accepted that sepsis 
involves aspects of both excessive inflammation and immunosuppression 
from the onset. Many of the issues in treating septic patients is the 
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difficulty in properly characterizing the immune status of the patients, 
leaving physicians uncertain of whether to try to suppress or enhance 
the patient’s immune system. Better stratification of patients’ immune 
status is critical for selecting proper treatments at the correct time. 
 
Costimulatory and Coinhibitory Receptors 
T cell activation classically requires two activation signals. The 
primary signal resulting from the binding between the APC MHC 
molecule and the TCR. A secondary signal is usually required to result in 
T cell activation and proliferation, and often is provided by CD28 on T 
cells interacting with either CD80 or CD86. 
Costimulatory and inhibitory receptors play a key role in the 
activation and suppression of the adaptive immune system. These 
receptors are cell-surface proteins that are involved in the interaction 
between APCs and T cells. They are expressed on APCs, which regulate 
adaptive immunity by regulating immune cell activation and inhibition, 
and therefore play a significant role in infections and the inflammatory 
response seen in sepsis. 
  The most well-known costimulatory members are CD80 (B7-1) and 
CD86 (B7-2), part of the B7 family. CD86 is constitutively expressed at 
low levels and its expression is rapidly increased after APC activation, 
whereas CD80 is induced hours or days after APC activation. CD80 and 
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CD86 interact with both the stimulatory CD28 and inhibitory CTLA-4 
receptors on T cells. CD28 signaling on T cells promotes T cell activation 
and survival. A study that used an agonistic CD28 monocloncal antibody 
on humans resulted in overwhelming inflammation and even death and 
showed many characteristics similar to those seen in sepsis 
(Suntharalingam, 2006). In contrast to CD28, CTLA-4 is an inhibitory 
receptor that is upregulated on T cells following activation and serves to 
limit the immune response. CTLA-4 expression is increased on T 
lymphocytes in patients with sepsis and is correlated with the 
downregulation of CD86 on monocytes (Roger, 2009). Whereas CD28 is 
constitutively expressed on naïve T cells, CTLA-4 is induced only after T 
cell activation, serving to limit the adaptive immune response by 
competing with the lower-affinity CD28 on APCs, as well as exerting a 
direct inhibitory impact on cells to inhibit T cell activation. (Alegre, 
2001).  CTLA-4 is also strongly expressed on immunosuppressive T 
Regulatory (TReg) cells, where it enhances their activity and proliferation 
(Che, 2007). 
 
CD40 and CD40L 
CD40 and CD40L(CD154) are a costimulatory pair that are part of 
the TNF superfamily and serve as a regulator of lymphocyte function, 
especially CD4 T cell activation (Grewal, 1996). CD40 is constitutively 
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expressed on APCs and B cells. Its ligand, CD40L (CD154) is 
predominantly expressed on activated T cells, macrophages, and 
platelets (Henn, 1998) (van Kooten, 2000). Classical activation of the 
CD40/CD40L pathway results in the development of APC function and 
increased expression of costimulatory molecules that serve to activate T 
cells during an immune response. The pathway also activates the NF-κB 
transcription factor, which is critical for its roles in inflammation. 
Activation of the CD40/CD40L pathway also results in production of IL-
6, an important inflammatory cytokine and its level is strongly correlated 
with disease severity in sepsis (Clark, 1990) (Remick, 2005). 
 
PD-1/PDL1 
 PD-1 is a more recently discovered inhibitory receptor of the B7 family 
that is found primarily on activated CD4 and CD8 T cells, but also B 
cells and monocytes. The PD-1 receptor has 2 known ligands: PD-L1 (B7-
H1) and PDL2 (B7-DC). PD-L1 is currently thought to be the more 
important of the two ligands and is expressed on both hematopoetic and 
non-hematopoietic cells. PD-L1 expression has been characterized on 
dendritic cells (DCs), macrophages, monocytes, B cells, endothelial cells, 
and other cell types (Keir, 2008). Lymphocytes and monocytes are 
thought to be primarily involved in the PD-1/PD-L1 pathway especially 
during infection (Sharpe, 2007). When the PD-1 receptor is activated by 
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its ligand it exerts strong inhibitory effects on the immune response and 
is involved in regulating cytokine production, T cell activation, tolerance, 
and apoptosis. There is currently intense interest in the PDL1-PD1 
pathway as it has been shown to play roles in sepsis, cancer, HIV, and 
other diseases. Recent studies have indicated that blocking of the PDL1-
PD1 pathway improves survival in sepsis by increasing monocyte 
responsiveness and decreasing lymphocyte apoptosis (Zhang, 2010). PD-
1 is also highly expressed on the immunosuppressive T Regulatory cells, 
which play a major role in inducing CD8+ T cell anergy (Csoka, 2007). 
  In the past several years, the role of neutrophils as solely innate 
immune cells has been called into question. Many studies have 
presented significant data suggesting the involvement of neutrophils in 
regulating the adaptive immune system (Ostanin, 2012) (Culshaw, 2008). 
Specifically, recent studies have provided support that neutrophils can 
express PDL1 and even alter the adaptive immune response by 
interacting with T cells (Huang, 2014). A recent 2014 study indicated 
that neutrophil PDL1 expression was induced by IFN-α, HIV-1 virions, 
and multiple TLR ligands including LPS (Bowers, 2014). 
 
Adenosine 
Adenosine was first postulated to act as an extracellular signaling 
molecule in 1929 when Szent-Györgyi and Drury injected heart muscle 
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extracts into animals and noted a decreased heart rate in those subjects 
(Drury & Szent-Györgyi, 1929). The molecule responsible for decreased 
heart rate was identified as adenosine, and adenosine has been used 
therapeutically since the 1980s to decrease heart rate in humans 
(diMarco, 1985).  
More recent studies have supported the role of adenosine as a 
potent immune regulator. During normal conditions extracellular 
concentrations of adenosine are negligible, however adenosine 
accumulates extracellularly in response to stresses such as inflammation 
and hypoxia (Bodin & Burnstock, 1998). In line with this evidence, it has 
been shown that septic patients have significantly elevated levels of 
adenosine in their blood compared to controls (Kaufmann, 2007). 
Adenosine binds to four different cell-surface receptors: A1, A2A, 
A2B, and A3. All four of these receptors exert their effects mainly through 
G-coupled proteins, although some G-protein-independent mechanisms 
have been suggested (Fredholm, 2007). The adenosine pathway has been 
implicated to play major roles in the immunosuppression seen in 
infection and in the tumor microenvironment, both of which are known 
to have increased adenosine accumulations. Although a detailed look at 
all four of these adenosine receptors is beyond the scope of this work, the 
reader is highly encouraged to consult two excellent reviews on 
purinergic signaling and receptor subtypes (Burnstock, 2013) (Bours, 
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2003). 
The A2-receptors (A2A and A2B) are coupled to GαS-proteins and 
induce adenylyl cyclase and cAMP buildup inside cells (Fredholm, 2007). 
The high-affinity A2A-receptor has received significant attention and is 
speculated to be the most important adenosine receptor for regulating 
immune responses. It is highly expressed on many different immune 
cells including: neutrophils, macrophages, monocytes, mast cells, T cells, 
MDSCs, eosinophils, basophils, NK cells, dendritic cells, and others. 
Studies have shown that agonists of adenosine exert a range of 
immunosuppressive responses on these cells mainly via the A2A receptor 
(Blackburn, 2009). Figure 1 depicts some of the various effects that 
adenosine has on immune cells when it activates the A2A receptor 
pathway. 
One of the main suppressive effects of A2AR activation occurs due 
to the increased production of IL-10, which is a key immunosuppressive 
cytokine. IL-10 inhibits the production of pro-inflammatory cytokines 
such as IL-6, IL-12, and TNFα. IL-10 also decreases antigen presentation 
by decreasing MHC-II expression, down-regulates costimulatory molecule 
expression, and decreases immune cell recruitment by down-regulating 
chemokine production (Couper, 2008). The adenosine pathway seems to 
exist to limit excess collateral damage in the setting of inflammation, 
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which indicates it is an important inborn control mechanism of the 
immune system. 
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FIGURE 1: Cellular Effects of A2AR Activation on Immune Cells  
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Current Study 
Sepsis is an extremely complicated syndrome that presents many 
incompletely understood immune dysfunctions and is characterized by a 
high mortality rate. An important goal in sepsis research is to further 
understand the pathophysiology and the immune alterations that occur 
in the different stages of sepsis, and how these alterations impact 
survival outcome and long-term immune alterations.  
Recent data have demonstrated a role for adenosine as a signaling 
molecule in pathological environments such as inflammation, tumor 
microenvironments, and in hypoxic/ischemic tissues. Accumulating 
evidence suggests a potent role for adenosine molecules in altering the 
immune response and serving as an inborn negative feedback 
mechanism during inflammation.  
This study will use a well-regarded technique to induce a mixed 
polymicrobial infection that elicits immune effects similar to those seen 
in peritonitis. This technique, Cecal Ligation and Puncture (CLP) is 
considered a top-notch research technique for emulating sepsis. 
There were three primary aims in undertaking this study. 
#1: Does antagonism of the adenosine 2A receptor alter mortality in 
sepsis? 
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#2: Does administration of an adenosine 2A receptor antagonist alter the 
expression of CSMs during sepsis? 
#3: Does adenosine 2A receptor antagonism alter the plasma cytokine 
profile of septic mice in comparison to untreated septic mice at 24 hours 
post CLP? 
We plan to examine these specific aims through the utilization of a 
murine CLP model of sepsis. We will then administer an adenosine 2A 
receptor antagonist and examine the overall effect on mortality by 
following the survival of the mice and analyzing their survival by log-rank 
analysis. At 24 hours post-surgery we will take a small amount of 
peripheral blood and separate the cells from the plasma. The plasma will 
be used to study cytokine expression in septic mice, either treated or 
untreated, at 24 hours post-surgery. We will then use the cell pellet to 
stain for CSMs expression to be analyzed by flow cytometric analysis. 
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METHODS 
 
 
Animals 
Female 8-12 week old (~20-25g) outbred ICR mice (Harlan-Sprague 
Dawley, Indianapolis, IN) were used for all studies. Mice were acclimated 
in the animal housing room for a minimum of 24 hours before 
experiments in a temperature and humidity-controlled room on a 12 
hour light-dark cycle. Mice were allowed access to food and water ad 
libitum. All experiments were approved by the Boston University Animal 
Care and Use Committee. 
 
Sepsis Model 
The Cecal Ligation & Puncture (CLP) model as originally developed by 
Wichterman and Chaudry with slight modifications was utilized to 
simulate a septic state resulting from intra-abdominal peritonitis 
(Wichterman & Chaudry, 1980). Mice were briefly anesthesized with 4% 
isoflurane and a midline abdominal incision of ~3cm was created. The 
cecum was exposed and ligated distal to the ileocecal valve with a 4-0 
USP braided silk suture. The cecum was then punctured twice 
longitudinally with a 16-gauge needle, and the cecum was gently 
squeezed to extrude a small amount of fecal content to ensure wound 
patency.  The cecum was returned to the abdomen, the abdominal wall 
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closed with sutures, and the skin closed with wound glue. This CLP 
method resulted in ~50% mortality in the first 5 days after surgery, 
representing an acute model of sepsis. Pain management consisted of 
Buprenorphine (.05 mg/kg; sc) every 12 hours for the first 2 days post 
surgery. Broad-spectrum antibiotics were administered every 12 hours 
for 5 days (Imipenem 25 mg/kg; sc) beginning 1.5 hours after CLP to 
emulate the standard treatment for human sepsis.  
 
For A2A receptor antagonist studies, mice were administered SCH-58261 
(10 mg/kg, dissolved in DMSO) at 6-hours post CLP by s.c. injection 
once daily for 2 days, and control mice were given vehicle (DMSO + 
saline).  
 
Telemetry Live/Die Stratification  
Prior work done by our lab has indicated that mice that have undergone 
CLP can be stratified into those predicted to live (P-live) and those 
predicted to die (P-die) at 6 hours post-CLP based on heart rate. Mice 
with a heart rate of >700 b.p.m. were predicted to survive and those with 
a heart rate of <550 b.p.m. are predicted to die. Mice with heart rates 
between 550 and 700 were not stratifiable, and thus excluded from 
analyses. Mice that were treated with the A2A receptor antagonist were 
treated at this time, after the stratification into P-live and P-die groups, 
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and then treated one additional time 24 hours after this initial treatment. 
 
Blood Sampling 
Sampling occurred at 24 hours post-CLP surgery via facial vein 
puncture. 50µL blood was aspirated via a pipette with a pre-rinsed tip to 
prevent clotting. The blood was diluted in a 150µL PBS solution (1X PBS, 
3.38mM EDTA, and 2% FCS) and centrifuged at 300g at 4°C, and the 
plasma was collected and stored at -80°C until further analysis.  The 
cells were then resuspended and the red blood cells were lysed, 
centrifuged, the supernatant was aspirated off, and the remaining cell 
pellet was collected for flow cytometric analysis. 
 
Flow Cytometry 
The following antibodies were used for flow cytometry 
monocyte/granulocyte staining: BV421-conjugated anti-CD11b, APC-
Cy7-conjugated anti-Ly6C, PerCPCy5.5-conjugated Ly6G, BUV395-
conjugated anti-CD86, APC-conjugated anti-CD40, BV605-conjugated 
anti-MHCII, PE-conjugated anti-PDL1, and FITC-conjugated anti-NKp46. 
The lymphocyte staining antibodies consisted of: FITC-conjugated anti-
CD3, PerCP-conjugated anti-CD4, APC-H7-conjugated anti-CD8, 
BUV395-conjugated anti-CD25, BV737-conjugated anti-CD69, BV421-
conjugated anti-CD28, PE-conjugated anti-PD1, PE-Cy7-conjugated anti-
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CD40L, and APC-conjugated anti-CTLA-4. Compensation beads were 
also utilized. All antibodies were purchased from BD Biosciences (San 
Diego, CA). Flow cytometry was performed on a BD LSRII flow cytometer 
(BD Biosciences) and the data was analyzed with FlowJo software (Tree 
Star). 
 
Cytokine Analysis 
IL-6, MIP-2, and IL-12 were assayed from commercially available 
enzyme-linked immunosorbent assay (ELISA) kits (R & D Systems, 
Minneapolis, Minn.) All samples were run in duplicate. 
 
Statistics 
Statistics were performed using Prism 6 (GraphPad, San Diego, CA). For 
comparison between two groups, an unpaired t test for normally 
distributed data or the Mann-Whitney U test for data that did not follow 
a normal distribution was used. For group analyses one-way ANOVA was 
used for normally distributed data and the Kruskal-Wallis test was used 
for groups that did not display a normal distribution. Values presented 
are expressed as means ± SEM. Survival was analyzed by Kaplan-Meier 
analysis. 
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RESULTS 
 
 
A2AR antagonism increases mortality in an acute model of sepsis 
Mice predicted to live that were untreated had an overall survival 
rate of ~85% at the end of 14 days. In contrast, mice that were originally 
predicted to survive and subsequently treated with the A2AR-antagonist 
had a survival rate of ~23% at the end of 14 days. This difference was 
significant (p=.0003). Mice that were predicted to die in both the 
untreated group and the group treated with the A2AR-antagonist had a 
0% survival rate. 
 
FIGURE 2: Survival Curve P-live mice treated with the A2AR antagonist 
experienced increased mortality in comparison to P-live mice treated 
solely with vehicle (p=.0003). Mortality was 100% in both P-die control 
and P-die treated mice. Mice were monitored for survival for 14 days, and 
no additional deaths occurred after this period when survival was 
monitored for 30 days. 
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PDL1 expression is increased on neutrophils in P-die mice 
Neutrophils from P-die mice showed higher expression of PDL1 
than P-live mice after CLP. This difference was statistically significant 
(p=.0034) (Figure 3). Flow cytometry data indicated that there were two 
distinct neutrophil populations, one subset expressing high amounts of 
PDL1 and the other subset with low PDL1 expression (FIGURE 4). This 
subset of PDL1-high expressing neutrophils was not seen in control 
healthy mice as can be seen in FIGURE 5.  
 
 
FIGURE 3 Neutrophil PDL1 Expression PDL1 expression was 
significantly increased (p=.0034) on mice that were predicted to die after 
CLP when compared to P-live mice. 
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FIGURE 4 Neutrophil Flow PDL1 Expression on P-die Mice P-die mice 
showed two subsets of neutrophils that expressed different levels of 
PDL1. Neutrophils were gated by Ly6G, a rather specific neutrophil 
marker. 
 
 
FIGURE 5 Neutrophil Flow PDL1 Expression of Healthy mice Healthy 
mice did not show a PDL1-high subset like the septic mice. 
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A2AR antagonism increases CD86 expression on inflammatory 
monocytes 
Treatment with the A2AR antagonist increased the expression of 
CD86 on monocytes. P-live mice treated mice showed a CD86 expression 
of 1407±59 compared to P-live control mice 1124±16, and this difference 
was statistically significant p<.0001. Figure 6 
 P-die mice treated with SCH-58261 also showed an increase in 
CD86 expression (1540±99) compared to P-die control mice (1213±52), 
and this difference was also statistically significant (p=.0425). However, 
there was no statistically significant difference in CD86 expression 
between the P-live control mice and P-die control mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6 CD86 Expression on Inflammatory Monocytes Treatment 
with the A2A-antagonist significantly increased CD86 expression in both 
treatment groups, however P-live control and P-die control mice showed 
no significant difference in CD86 expression. 
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A2AR antagonism increases MHCII expression on peripheral blood 
monocytes 
Mice that were predicted to live and treated with the A2AR 
antagonist showed a significant (p=.0025) elevation in MHCII expression 
on peripheral blood monocytes (174.5±15) in comparison to control mice 
predicted to live (125.51±3). P-die A2AR antagonist treated mice also 
showed increased expression of MHCII compared to the P-die control 
mice, but this difference was not statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7 MHCII Expression on Monocytes P-live mice treated with 
the A2AR-antagonist showed significantly increased MHCII expression in 
comparison to P-live control mice (p=.0025). 
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P-die mice show elevated PDL1 expression on peripheral blood 
monocytes  
PDL1 expression was increased on the inflammatory monocyte 
subset of P-die mice (3453±1384) in comparison to P-live control mice 
(359.5±174) and this difference was significant (p=.0081). Figure 8 
Treatment with SCH-58261 did not appear to affect levels of PDL1 
18 hours after treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 8 PDL1 Expression on Inflammatory Monocytes PDL1 
expression was significantly greater on P-die mice than P-live mice 
(p=.0081), however treatment with SCH-58261 did not appear to affect 
PDL1 expression in peripheral blood monocytes. 
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A2AR antagonism increases CD40 expression on monocytes 
P-live control mice showed decreased CD40 expression 
(393.5±48.55) in comparison to P-die control mice (1039±269.9), and this 
difference was statistically significant (p=.0042) Figure 9 
 CD40 expression was also increased in P-live mice treated with 
SCH-58261 and this result was significant in P-live mice (p=.0063). P-live 
control mice had a level of CD40 expression of 393.5±48.55, whereas P-
live mice treated with the A2AR antagonist exhibited an increased CD40 
expression of 1226±337.9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 9 CD40 Expression on Monocytes CD40 expression on P-live 
control mice was lower than P-die control mice. Treatment with SCH-
58261 increased CD40 expression in both groups, however it was only 
significant in the P-live group (p=.0063).  
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A2AR antagonism increases cell activation marker CD69 in CD4 T 
cells 
P-live mice treated with A2AR antagonist showed increased 
expression of the cell proliferation marker CD69 (93.63±14.99) on CD4 T 
cells in comparison to P-live control mice (56.06±4.557), and this 
difference was significant (p=.0077). Figure 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 10 CD69 Expression on CD4 T Cells P-live mice treated with 
the A2A-antagonist showed increased expression of CD69 on CD4 T 
lymphocytes in comparison to P-live control mice, and this increase was 
statistically significant (p=.0077). 
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A2AR antagonism increases cell activation marker CD69 in CD8 T 
cells 
Mice treated with A2AR antagonist showed increased expression of 
the cell proliferation marker CD69 on CD8 T cells in comparison to 
control mice, but this difference was not statistically significant. Figure 
11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 11 CD69 Expression on CD8 T Cells While mice treated with 
the A2A-antagonist showed increased expression of CD69 on CD8 T 
lymphocytes, the increase was not significant (p >.05) 
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A2AR antagonism increases IL-12 in plasma 
 
IL-12 levels were increased in both P-live treated and P-die treated 
mice, with respect to their controls. For the P-die mice this difference was 
statistically significant (p=.0397). Figure 12 
Nonparametric ANOVA analysis revealed that the median between 
each group varied significantly (p<.0120). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 12 Plasma IL-12 Concentration at 24 Hours P-die treated 
mice showed increased IL-12 concentrations in peripheral blood at 24 
hours post-CLP, and this elevation was significant (p=.0397). 
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P-die mice show elevated pro-inflammatory IL-6 in plasma 
Control mice that were initially predicted to die showed 
significantly increased IL-6 levels in comparison to the control mice that 
were predicted to live. P-live vehicle treated mice had a plasma IL-6 
concentration of 1060±483.3, whereas P-die control mice IL-6 levels were 
elevated to 45725±15848. The difference in means was statistically 
significant between these two groups (p=.0149). Figure 13 
The A2A receptor antagonist did not appear to significantly affect 
plasma IL-6 levels at 24 hours (18 hours after treatment). There were no 
statistically significant differences between the P-live treated and P-live 
control mice, nor between the P-die treated and P-die control mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 13 Plasma IL-6 Concentration at 24 Hours P-die mice had 
higher concentrations of IL-6 in peripheral blood at 24 hours Post-CLP. 
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P-die mice show elevated MIP-2 in plasma at 24 hours after CLP 
 
Control mice that were predicted to die had a concentration of 
110800±32901, whereas mice that were predicted to live had 
significantly less MIP-2 with a mean 3340±1413 in their plasma at 24 
hours after CLP. This difference in MIP-2 concentrations was statistically 
significant (p=.0115). Figure 14  
The A2A receptor antagonist did not appear to significantly affect 
plasma MIP-2 levels at 24 hours (18 hours after treatment). There were 
no statistically significant differences between the P-live treated nor P-die 
treated mice with their respective controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 14 Plasma MIP-2 Concentration at 24 Hours P-die mice 
showed increased MIP-2 in peripheral blood at 24 hours post-CLP with 
regard to P-live mice. 
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DISCUSSION 
 
 
A2AR antagonism increased mortality in septic mice that were 
initially predicted to survive at 6 hours. This is in contrast to findings 
from another study in which inactivation of the A2A receptor increased 
survival in septic mice (Nemeth, 2006). However, our findings are in 
agreement with a study by Sullivan in which A2A receptor activation 
improved survival in a mouse model of endotoxemia (Sullivan, 2004). 
These differences may result from differing degrees of severity in the CLP 
model used. Additionally, our model utilized antibiotics to emulate the 
standard treatment for human sepsis, but could result in a rapid drug-
induced killing of vast quantities of bacteria, which could cause a rapid 
exaggerated immune response. In this situation, A2AR activation may 
prove beneficial by controlling the exaggerated response brought on by 
the drug-induced bacterial killing. Normally A2AR activation results in 
significant immunosuppressive effects, and it seem like that by blocking 
the adenosine receptor there was significantly increased inflammation. 
This increased inflammation would be harmful during an acute hyper-
inflammatory stage seen with our CLP model.  
Our data show that MHCII expression was increased on mice 
treated with the A2AR antagonist. This increased MHCII expression 
suggests improved antigen presentation. It is well known that decreased 
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antigen presentation is commonly seen during the immunosuppressive 
aspects of sepsis. Antagonism of adenosine receptors could be used 
therapeutically to enhance antigen presentation in order to enhance 
immune functions during an immunosuppressed state.  
The role of the PDL1/PD1 pathway is incompletely understood at 
this time. Upregulation of PD-1 and PD-L1 on T cells, B cells and 
monocytes during sepsis has been regularly reported and blocking of this 
pathway has appeared to be beneficial in reducing lymphocyte apoptosis 
and T cell anergy commonly seen in sepsis (Zhang 2010). 
A study showed that during sepsis CD40 expression is increased 
on peripheral blood monocytes and that the expression was positively 
correlated with survival (Sugimoto, 2003). However, another group 
reported decreased mortality in CD40-/- mice compared to WT mice after 
CLP (Gold et al, 2003). Based on our results that P-live control mice 
actually had lower expression of CD40 in comparison to P-die control 
mice, it seems plausible that in CD40 could exacerbate inflammation and 
increase mortality in an acute model of sepsis that is characterized by an 
hyper-inflammatory immune response. Additionally, because the A2AR 
antagonist significantly increased CD40 expression in our P-live mice, it 
seems likely that this increase also resulted in exacerbated inflammation 
and the subsequence increased mortality in the P-live treated mice. 
These finding suggest that an adenosine receptor antagonist might be 
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better suited for application during a more chronic model of sepsis that 
is characterized by significant immunosuppression.  
Upregulation of CD25 on treated P-live mice as expected. This is in 
agreement with other studies that indicated a decrease in CD25 
expression when mice were treated with an adenosine agonist (Sevigny, 
2007). However, an increase in CD25 could represent an increase in TRegs 
that are involved in immune suppression. Future studies that can stain 
for TRegs in flow cytometry via the intracellular FOXP3 protein or another 
T regulatory cell-specific marker will be required to examine this 
possibility. 
The increased expression of the cell activation marker CD69 
support our hypothesis that by antagonizing the A2A receptor more cells 
become activated and proliferate. This finding is compatible with many 
studies that show that A2AR agonists increase lymphocyte apoptosis and 
anergy. Treatment with A2AR antagonists should be more carefully 
examine as a therapeutic option for increasing lymphocyte activity and 
decreasing apoptosis to combat immune suppression. 
MIP-2 levels were significantly elevated in mice that were predicted to die 
in comparison to mice predicted to live. This is in agreement with a 
previous study by Ebong in which MIP-2 levels were also elevated in mice 
that subsequently died of sepsis (Ebong, 1999). Treatment with SCH-
58261 did not appear to impact MIP-2 levels in the plasma 18 hours 
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after its administration. This could be due to timing of plasma sampling 
or SCH-58261 dosing effects, and future experiments will be needed to 
clarify these results. 
Adenosine plays a significant role in the immune response and 
offers a unique therapeutic strategy that should be researched more in 
the future. It will be important in any future application of adenosine 
agonists and antagonists to consider the timing and phase of sepsis. 
During an intense hyper-inflammatory condition the use of an adenosine 
antagonist might exacerbate inflammation and organ damage, whereas 
the use of an antagonist would be better suited for a patient that exhibits 
immunosuppression. Patients with sepsis display marked heterogeneity, 
and better stratification is critical to the application of any future sepsis 
treatment. Future studies of the A2AR-antagonist that utilize a more 
chronic model of sepsis that results in longer survival time and 
significant immunosuppression will be interesting to examine. 
Additionally, it will be worthwhile to examine the effects of adenosine 
receptor antagonism at a local level, by studying cells directly from the 
peritoneum. It has become very clear that adenosine receptors are 
critically involved in regulating the immune response and that 
treatments focused on modulating adenosine pathways may provide 
remarkable results for the treatment of immune dysfunctions seen in 
sepsis and other diseases. 
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